Marijuana Stocks

MKM Partners initiated coverage of five Canadian cannabis companies and two U.S. multi-state operators on Friday with a cautious outlook, arguing that the current business model of cultivation will become commoditized and make it difficult for companies to build strong brands.

As Global X launches a fresh pot ETF, let's explore the product in detail.

Hall of Flowers has become one of the leading events in the cannabis industry, especially for B2B networking – needless to say, the Benzinga Cannabis Capital Conference remains our favorite investor-focused ...

Cannabis investing enthusiasts now have a sixth exchange traded fund to consider following the Thursday debut of the Global X Cannabis ETF (NASDAQ: POTX ). POTX tracks the Cannabis Index, making it the ...

MJ, The ETFMG Alternative Harvest ETF , the largest cannabis ETF in the world, has declared an approximate $10.6 million quarterly dividend which equates to $0.28 per share.

The Viridian Cannabis Deal Tracker is an information service that monitors capital raise and M&A activity in the legal cannabis industry. Analyzing within 12 key industry sectors, the Viridian Cannabis Deal Tracker provides cannabis companies, investors, and acquirers with the data, trends, and intelligence they need to make informed decisions regarding deal valuations, terms, and structures. Since its inception, the Viridian Cannabis Deal Tracker has tracked and analyzed more than 2,400 capital raises totaling over $29 billion as well as more than 800 M&A transactions.

The Benzinga events team continues to bring top-notch events to leading markets like New York City, San Francisco, Toronto, Miami, Detroit — and now Chicago. If you consider yourself to fall into the following categories, our Cannabis Capital Conference may not be the best fit. If not, the Benzinga Cannabis Conference is the ideal place to make connections, learn about the space and find your next investment.

Hydroponics Inc., a national provider of agricultural supplies and logistics specific to the cannabis and hemp industries, is launching a multi-million-dollar special acquisition fund. The company said it will deploy up to $75 million to acquire tangentially-related service businesses within the North American cannabis industry over the next 24 months. The company told Benzinga the goal is to construct a portfolio of established companies characterized by profitable operating histories, high-margins, and low customer concentration - all against the backdrop of a data-driven platform.

Podcast via Kannaboomers . “ This is a social movement that is moving forward faster than any other social movement in the world and probably in history. “ — Javier Hasse History is being made, day by ...

Pluto is officially debuting this week at famed cannabis event Hall Of Flowers. “At Pluto, you will find a diversity of characters, from overlapping decades, peacefully coexisting with one another. Pluto is a cannabis concentrates maker.

The next day, it seems that CBD products and their advertisements are everywhere. Thanks to the Hemp Farming Act of 2018 signed by Donald Trump, CBD products are not only widely available in the US but is now very high demand. The farm bill made industrial hemp legal in addition to legalizing recreational and medical cannabis at the state level.

The launch of four new cannabis ETFs in 2019, paired with the recent filing for yet another one, has many investors wondering how to navigate amongst the options as they seek exposure to the growing cannabis industry. The oldest and still largest cannabis ETF on the market is the ETFMG Alternative Harvest ETF (NYSE: MJ). The MJ investment objective is quite broad, and an examination of the portfolio indicates more than 17% is allocated to tobacco stocks, with other sizable positions including fertilizer companies, breweries and real estate investment trusts (REITs).

The Viridian Cannabis Deal Tracker is an information service that monitors capital raise and M&A activity in the legal cannabis industry. Analyzing within 12 key industry sectors, the Viridian Cannabis Deal Tracker provides cannabis companies, investors, and acquirers with the data, trends, and intelligence they need to make informed decisions regarding deal valuations, terms, and structures. Since its inception, the Viridian Cannabis Deal Tracker has tracked and analyzed more than 2,400 capital raises totaling over $29 billion as well as more than 800 M&A transactions.

Florida has so much untapped marijuana and hemp potential. In Florida, medical marijuana is available for serious health conditions such as cancer, Crohn’s disease, multiple sclerosis and post-traumatic stress disorder, and chronic pain associated with those conditions. Since the state’s introduction of its medical marijuana laws in January of 2017, Florida has enrolled 350,000 patients according to the August 23, 2019 report from the Office of Medical Marijuana Use.

It’s been a busy year for the California legislature, and like most of the previous seasons, cannabis has been at the top of lawmaker’s desks. Oct. 13 is the last day for Gov. Gavin Newsom to sign or veto bills passed by the legislature on or before Sept. 13. The Budget Trailer Bill, also known as Assembly Bill 97, was the most significant milestone for the California cannabis industry, said Josh Drayton, the communication and outreach director for the California Cannabis Industry Association.

Since hitting a 52-week high of $8.40 in April, Hexo (NYSE:HEXO) slid down for the last several months and has since been trading sideways within the $4-$4.50 range. In fact, HEXO stock, now in negative territory for 2019, has lagged other pot stocks generally as compared to the Alternative Harvest ETF (NYSE: MJ).Source: Shutterstock That MJ exchange-traded fund is up slightly by 1.4% for the year. HEXO stock is the seventh-largest holding in the fund's 37-pot stocks portfolio. Now with the fall investor season in full swing, Hexo may be finally ready to break out of the trading band after their next quarterly earnings call later today.The cannabis sector is well known for highly cyclical boom and bust trends. When trading finally moves from sideways to a bounce back, here are three key reasons why Hexo is a pot stock to watch. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Canada's Cannabis 2.0 Around the CornerHexo is one of the Big Five Canadian cannabis stocks. As such, Hexo stock will likely be a prime target of investor interest next month. As part of the ongoing process of national legalization of cannabis in Canada, Oct. 17 marks the date when it becomes legal to sell cannabis extracts. The first round of legalization in Canada began in 2018 but applied only to dried marijuana. The legislation scheduled to take effect next month will bring into the Canadian market a vast range of cannabis-infused edible products that will be far more appealing to a broader audience."The edibles market is estimated to be worth at least $1.6 billion a year in Canada, with cannabis-infused beverages adding a further $529 million," according to Jennifer Lee, Deloitte Canada's Cannabis national lead. "The introduction of cannabis-infused edibles will clearly threaten the alcohol industry as consumers are using the product for similar usage occasions," she wrote recently. * 7 Deeply Discounted Energy Stocks to Buy Hexo has been patiently waiting to pounce on the newly expanded market and has already developed cannabis-infused gummy candies, a premium vape line as well as several cannabis-infused beverages. Powered by Hexo: Innovation will Protect MarginsAs the global cannabis market expands, commodification is inevitable. That is, a bulk of consumers may simply seek their best bang for the buck.Generic cannabis producers focusing purely on high output and low price could get caught in a price squeeze. Seeing the long-term direction of the market, Hexo has invested heavily in R&D and product innovation to enhance the brand value of a "Powered by Hexo" product line. "Building our innovative technology is critical in building a brand. We believe that brand will be the final moat by which CPG cannabis companies are differentiated," explained Sebastien St-Louis, Hexo co-founder and CEO, on a recent earnings call."We're continuing to expand our R&D and innovation team with top scientists, chemists who have extensive experience in CPG companies. We now have 25 PhDs on staff. They're focused on developing new and innovative products for the market and best-in-class technology for our Powered by HEXO experiences," he said Strong Top Line RevenuesThe global cannabis market is still in the very early stages where firms are focusing primarily on building infrastructure, expanding distribution channels, and creating a market presence among new consumers.While Hexo is certainly building production capacity and distribution as well as creating a valuable brand identity, it is undoubtedly furiously growing top-line revenue. Hexo's total gross revenue was CAD 15.9 million ($12.05 million) for Q3 2019, 11.8x over the same quarter in 2018. Hexo expects revenue to double in Q4 2019, particularly as it starts to expand aggressively beyond Quebec. * The 8 Worst Stocks to Buy Before the Trade Turmoil Cools Off Undoubtedly, there is much risk inherent in Hexo's financials, as well as the entire pot stock sector. Hexo operating cash flow is negative, and operating losses continue to mount. Further, many investors are becoming wary of the ebbs and flows of political sentiment about new cannabis laws in the US, where the Republican-controlled Senate has so far expressed near-zero support for legalization.However, all these risks are already well and truly baked into the Hexo stock price. A favorable earnings call this month may be all it takes to see Hexo stock rebound for its current sideways trading pattern. Given the intraday volatility, Hexo may be a good buy on any market dip.As of this writing, Theodore Kim has no positions in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks to Sell in Market-Cursed September * 7 of the Worst IPO Stocks in 2019 * 7 Best Stocks That Crushed It This Earnings Season The post As Canadians Get Ready for Edibles, is Hexo Stock Ready to Bounce? appeared first on InvestorPlace.

Federal drug enforcement officials want to boost the amount of marijuana that can be legally produced for research in the United States while cutting the number of opioids that can be manufactured in the country. The U.S. Drug Enforcement Administration said in a press release Wednesday that it will propose to boost the amount of marijuana produced for research next year by nearly a third, to 3,200 kilograms. The agency said that over the last two years the number of people registered by the DEA to conduct research with marijuana, marijuana extracts and derivatives has increased by more than 40%, making the increase in production necessary.

Investors betting against cannabis companies have much to celebrate as stocks in the sector sputter and swoon.

Despite growing sales and wider legalization, many pot stocks have been insanely volatile as Wall Street and investors try to wrap their heads around the marijuana industry. So should you think about buying "cheap" Aurora Cannabis (ACB) Stock before Q4 earnings?

Watch the author’s track record on TipRanksThe cannabis sector has seen an unusual pattern of executives agreeing to extended share lock-up extensions due presumably that insiders are looking to dump shares. Tilray (TLRY) is the latest company to finalize a lock-up agreement that adds more confusion than safety for the stock now trading all the way down at $30.Adds Confusion The biggest question for Tilray investors is why the executives even need to make an agreement, so the top shareholder won’t sell shares. What does Privateer matter considering the initial investors hold 75 million Tilray shares or 77% of Tilray’s total shares.Privateer can’t unload shares without cratering the stock so a lock-up that extends the holding period a couple of more years doesn’t delay the ultimate risk in the stock. If anything, this move adds confusion for an IPO completed over a year ago where any lock-up would have already been over and the market would have more confidence that the leading shareholders aren’t looking to unload shares.The deal includes limits on any share sales during the first year arranged at the sole discretion of Tilray. At the end of the first year, 50% of the 75 million shares subject to the lockup will be released. Over the course of the second year, the remaining shares will be subject to a staggered release in equal quarterly increments.The Privateer ownership is controlled by equal 16.7 million shares by CEO Brendan Kennedy, Christian Groh and Michael Blue. The remaining 24.9 million shares are held by other Privateer shareholders.Such a complicated lock-up release covering over three years from the IPO suggests that one of the large investors wants to exit their position. The move causes the overhang on the stock to linger.Doesn’t Add ValueThe stock initially popped on the news, but this final agreement was only an extension of an agreement from back in June. Tilray ended down over 6% following the news.Ultimately, one has to see limited risk that Privateer shareholders that include CEO Brendan Kennedy would attempt to sell stock with the market value down to $3 billion. The cannabis company supposedly has big global plans so any move to dump shares here at the all-time lows would crater the stock.What the market needs is for all of these Privateer shareholders to actually resist from selling shares. Anybody buying shares now has to face a lockup overhang of 37.5 million shares next September. The following lockup during year two won’t matter as long as insiders aren’t dumping Tilray shares after the first share release.TakeawayThe key investor takeaway is that Tilray shareholders don’t need lockup extension deals that only push a big risk factor out a year or two. What they need is insiders buying shares after the stock has been beaten down or these insiders refusing to sell shares when freely permissible to dump shares.The bigger issue remains the $3 billion market cap and the 2020 sales target below $350 million. Maybe this valuation discrepancy is why the company is so concerned that insiders will start unloading shares without a lock-up extension for another year.Unsurprisingly, investor sentiment is negative, with individual portfolios in the TipRanks database showing a net pullback from TLRY.Disclosure: No position.